Meazza C., Galaverna F., Petris M.G., Zama D., La Spina M., Muggeo P., Ziino O., Cellini M., Soncini E., Barone A., De Santis R., Perruccio K., Mura R., Pascale S., Mercolini F., Cesaro S.
Prophylaxis of Pneumocystis jiroveci pneumonia (PJP) with trimethoprim/sulfamethoxazole is a standard of care for children with hematologic malignancies, while its use in solid tumor patients is still debated. A retrospective study focusing on the use of PJP prophylaxis in patients with solid tumors was performed among 16 AIEOP centers: 1046/2863 patients did not receive prophylaxis and no cases of PJP were reported.
